» Articles » PMID: 34430691

Case Report: -rearranged Cervical Sarcoma with Fibrosarcoma Like Morphology Presenting in a 13-year-old Managed with a Neo-adjuvant TRK-inhibitor and Surgical Excision

Overview
Publisher Elsevier
Date 2021 Aug 25
PMID 34430691
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

This case report reviews the case of a 13-year-old patient who presented with a 9 cm rearranged cervical sarcoma with fibrosarcoma like morphology. At presentation the lesion filled her vagina and pelvis and any attempt at surgical removal would have been morbid and led to loss of fertility. These neoplasms are extremely rare with 18 cases of the uterine cervix reported in the literature, none of which have occurred in a paediatric patient, and none of whom have received neo-adjuvant therapy prior to excision. Based upon evidence that has shown good tolerability and responses of paediatric fusion-positive solid tumours to TRK inhibitors, both in the neo-adjuvant and upfront setting, this patient was managed with neo-adjuvant entrectinib. Following a dramatic reduction in tumour size confirmed by imaging, she underwent conservative fertility sparing surgery with final histopathology showing no residual disease.

Citing Articles

NTRK rearranged spindle cell neoplasm of the uterine cervix: a rare case report and literature review.

Jiang X, Zhang S, Wu L, Li Z BMC Womens Health. 2025; 25(1):88.

PMID: 40011900 PMC: 11863720. DOI: 10.1186/s12905-025-03574-w.


TPM3::NTRK1-rearranged uterine sarcoma: case report and literature review.

Yang Y, Li L Int J Clin Exp Pathol. 2025; 17(12):477-486.

PMID: 39802876 PMC: 11711482. DOI: 10.62347/PTTF8718.


The mutual interplay between NTRK fusion genes and human papillomavirus infection in cervical cancer progression (Review).

Aziz A, Zhang J, Zhang C, Yu X, Wang D Mol Clin Oncol. 2024; 21(4):67.

PMID: 39091417 PMC: 11289753. DOI: 10.3892/mco.2024.2765.


Conservative surgical treatment with fertility preservation in a young adult with rearranged spindle cell neoplasm of the uterine cervix.

Buhler M, Honcharova-Biletska H, Pauli C, Chronas D, Bolten K Gynecol Oncol Rep. 2023; 48:101233.

PMID: 37415959 PMC: 10319898. DOI: 10.1016/j.gore.2023.101233.


Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.

Tsai J, Lee J, Hsieh T, Huang S, Lee P, Liu T Mod Pathol. 2022; 35(7):911-921.

PMID: 35149769 DOI: 10.1038/s41379-021-01005-3.

References
1.
Shulman D, Dubois S . The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs. 2020; 22(2):189-197. DOI: 10.1007/s40272-020-00380-9. View

2.
Laetsch T, Dubois S, Mascarenhas L, Turpin B, Federman N, Albert C . Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018; 19(5):705-714. PMC: 5949072. DOI: 10.1016/S1470-2045(18)30119-0. View

3.
Pulciani S, Santos E, Lauver A, Long L, Aaronson S, Barbacid M . Oncogenes in solid human tumours. Nature. 1982; 300(5892):539-42. DOI: 10.1038/300539a0. View

4.
Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2019; 21(2):271-282. PMC: 7461630. DOI: 10.1016/S1470-2045(19)30691-6. View

5.
Dubois S, Laetsch T, Federman N, Turpin B, Albert C, Nagasubramanian R . The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018; 124(21):4241-4247. PMC: 6263791. DOI: 10.1002/cncr.31701. View